Introduction {#S1}
============

Despite significant developments, conventional antidepressant treatments leave many older adults depressed and suffering^[@R1]^. Antidepressants developed in the past 20 years are safe but their efficacy is no better than that of tricyclics. The onset of antidepressant action is slow, improvement of symptoms is often incomplete and unstable, and remission occurs in only one third of patients^[@R2]^. In addition, if the patient suffers from executive dysfunction, they are almost two times less likely to respond to medications^[@R3],[@R4]^. Psychotherapy may be effective in some depressed elders, although a recent review concluded that none of the available treatment studies met stringent criteria for efficacy in the acute treatment of geriatric depression^[@R5]^. The recent National Institute of Mental Health (NIMH) report "From Discovery to Cure" calls for studies focusing on mechanisms of treatment response with the goal of arriving at new interventions for those who do not respond to existing treatments. It is in response to this report and our group\'s previous findings that we developed a treatment designed to change the functioning of a cerebral network we and others found associated with poor treatment response in geriatric depression^[@R6]-[@R10]^.

Replicated studies document that executive dysfunction in geriatric depressed patients leads to adverse clinical outcomes including poor and slow response to antidepressants^[@R11]-[@R18]^, disability^[@R19]^, increased risk for relapse^[@R20]^, and suicidal ideation^[@R21]^. In addition, executive dysfunction often persists despite remission of mood symptoms^[@R6],[@R22],[@R23]^, leaving patients perpetually vulnerable. Within executive functions, susceptibility to cognitive interference, and impairment in strategic semantic organization are two functions that have repeatedly been linked to poor remission rates independently of processing speed^[@R8],[@R14],[@R15],[@R24],[@R25]^.Last, more than 40% of elderly depressed patients suffer from executive dysfunction^[@R26]^, making it a common dysfunction, that if successfully treated, could significantly improve the treatment outcomes of late-life depression^[@R27]^.

Recent findings from both human^[@R28]-[@R31]^ and animal^[@R32]^ studies suggest that the aging brain can make neuroplastic changes with enhanced activity^[@R33],[@R34]^. Neuroplasticity-based computerized cognitive remediation (nCCR) has been shown to reverse age-related declines in information encoding and processing and induce change in the underlying neural functions^[@R29],[@R30]^. In older adults, nCCR improves basic cognitive functions such as memory^[@R31]^, and processing speed^[@R31]^, as well as executive functions such as cognitive control^[@R28]^, task shifting, resolving interference^[@R35]^, and dual task processing^[@R36]^. Further, nCCR training "generalizes" and induces both proximal and distal transfer^[@R31],[@R36]^. Effects of nCCR are also sustainable, with benefits remaining at least three months after training^[@R30]^. Finally, nCCR appears to induce changes on measures of "neuroplasticity" in the aging brain. nCCR-induced changes in brain structure and function^[@R37]-[@R39]^ in the elderly are similar to neurobiological effects in young adults, and correlate with improvements in cognitive performance^[@R38],[@R40]^.

Encouraged by the specificity of our cognitive findings, we designed Neuroplasticity-Based Computerized Cognitive Remediation for Geriatric Depression (nCCR-GD). We based the basic principles of nCCR-GD on the theory that neuroplasticity in an aged brain requires intensive practice coupled with the heightened neurotransmission associated with reward (modulated by dopamine and norepinephrine)^[@R41]^. To meet this goal we designed nCCR-GD behavioral training paradigms to engage targeted cerebral networks with sensory, motor and cognitive tasks that are: 1. Increasingly challenging; 2. Individually adaptive; 3. Attention demanding; and 4. Immediately rewarding.

nCCR-GD was designed to train depressed older adults on the specific executive functions that predict treatment response in geriatric depression (i.e. cognitive inhibition ^[@R14],[@R25],[@R42]^ verbal strategy initiation and utilization^[@R3],[@R4]^, as well as aspects of cognitive control that rely on overlapping networks (i.e. cognitive flexibility; set shifting; inhibition of prepotent responses). We aimed to target the cerebral networks (including: DLPFC, OFC, dACC) associated with these executive functions. Our selection of behavioral training paradigms to target executive functions for nCCR-GD was informed by other nCCR studies in normal older adults that demonstrated successful remediation of target executive deficits due to normal aging ^[@R29],[@R38],[@R43]^.

Our preliminary findings suggest that nCCR-GD may be equally effective as escitalopram in treating geriatric depression. In addition, nCCR-GD participants show greater improvement in clinically relevant executive functions than those treated with escitalopram alone. As a first step, we tested this intervention with depressed older adults who had failed at least one trial of an antidepressant (SSRI or SNRI) at an adequate dose for at least 8 weeks. The objectives of this study were: 1. To test the feasibility of this novel treatment modality in a geriatric depressed sample. 2.To compare our treatment (nCCR-GD for four weeks) to a control, gold-standard treatment (escitalopram; target dose:20mgs for 12 weeks). This study tests the hypothesis that nCCR-GR offered to geriatric patients with major depression who had failed at least one adequate antidepressant (SSRI or SNRI) trial will improve on measures of both executive functioning and depression more than those taking escitalopram alone. We also hypothesized that the nCCR-GD would improve not only the functions trained by the programs, but generalize to other executive functions that rely on networks similar to the targeted network ("near transfer").

Results {#S2}
=======

CCR-GD versus escitalopram {#S3}
--------------------------

Of the 11 participants, 10 completed the 4-week treatment (91%). At baseline, there were no differences (escitalopram vs. nCCR-GD) in MADRS (U=180.0, p=.967) in age U=173; p=.818), education (U=141.5; p=.273), age of onset (U=153; p=.440), or executive function (Trails B) (U=152; p=.424) ([Table 1](#T1){ref-type="table"}).

Mixed effects model analysis showed no significant group main effect (F(1,49.23)=0.019, p=0.892). However, the time effect (F(1,71.22)=30.97, p\<0.001) and treatment group × time interaction (F(1,61.8)=5.32, p=.024) reached significance indicating that the slope of MADRS decline was steeper in the nCCR-GD group ([Figure 1](#F1){ref-type="fig"} and [Figure 2](#F2){ref-type="fig"}).At the end of 4 weeks of treatment the mean MADRS score in the nCCR-GD group was 8.9 (sd 4.8), lower (t=3.052;df=38;p=.004) than the escitalopram group mean score 15.5 (sd=6.1).

nCCR-GD improved Trails B performance more than escitalopram (t=2.28, df=41, p=0.027)([Figure 3](#F3){ref-type="fig"}); and that there was a trend for the Stroop Color-Word (t=1.86, df=41, p=0.103)([Figure 4](#F4){ref-type="fig"}).

### CCR-GD Response rates {#S4}

Of the 11 patients, 9 patients met criteria for response to treatment at the end of four weeks.At the 12-week no-contact follow up, 6 of 11 patients met criteria for response to treatment

### CCR-GD Remission rates {#S5}

After four weeks 8 of the 11 patients met criteria for remission^[@R44]^. At the 12-week follow up, 6 of 11 patients met criteria for remission.

### Neurocognitive change in the nCCR-GD group {#S6}

In the nCCR-GD group, we conducted exploratory analysis of change in performance from baseline to treatment end (paired t tests) on targeted as well as transfer of benefit to non-targeted executive functions, and to distal cognitive functions that rely on intact performance of executive functions. There was a an improvement in performance on the Stroop Color-Word (t=-3.051; df=9 p=.014), Trails B (t=3.554; df=9p=.024) and design fluency-switching on the DKEF-S (t=-4.243;df=9;p=.002). There was a trend for semantic clustering on the DRS I/P (t=-2.236;df=9; p=.052) i.e. participants may have increased the number of semantic clusters they used to complete the DRS I/P. There was no pre- to post-nCCR-GD treatment difference in performance in working memory (WAIS-IV digits backwards (t=.197; p=.849)); or in verbal memory (CVLT-ii long delay recall (t=1.00; p=.347)). There was a correlation between improvements in Trails B performance before and after CCR-GD treatment with improvements in MADRS scores (Spearman\'s r =.723; p=.018), but not between improvements in the Stroop and improvements in MADRS scores (Spearman\'s r=.096; p=.560).

### 12-Week Follow-up After Completion of nCCR-GD {#S7}

Depressive symptoms: There was no significant difference in participants\' MADRS scores from treatment completion (week 4) to follow up 12 weeks later (t=-.505;df=9;p=.626). Cognitive Scores: There was no difference between scores on Stroop Color-Word (t=-1.155; p=.30), Trails B (t=.379;p=.720), Semantic Clustering (t=-1.00;p=.356), digits backwards(t=.444; p=.673); CVLT-ii Long delay recall (t=1.035; p=.348) or design fluency switching (t=-.573; p=.587) from the end of the treatment trial (4 weeks), to assessment at the 12 week follow up. These results suggest that the initial improvement in depressive symptoms as well as the neurocognitive gains made by nCCR-GD were sustained for at least 12 weeks (3 months) post treatment.

Discussion {#S8}
==========

The principal finding of this study is that nCCR-GD is feasible and equally effective with escitalopram in older adults with major depression. Ten of the 11 study participants completed the trial as prescribed. When compared to escitalopram treatment, nCCR-GD reduced MADRS scores to the same level in four as opposed to 12 weeks. Moreover, participants in then CCR-GD group were classified as treatment resistant; all had failed at least one adequate trial of an antidepressant. The escitalopram group was not similarly selected for treatment resistant participants.

This is the first study, to our knowledge, to document that an nCCR intervention targeting executive and related network functions can improve both mood and cognitive function in drug-resistant, late-life depression. In addition to the reduction in depression scores, nCCR-GD appeared to improve executive functions more than escitalopram; the nCCR-GD participants\' improved scores on a measure of cognitive flexibility (Trails B), over the treatment trial more than the escitalopram group, there was a trend for improvement of inhibiting prepotent responses (Stroop Color-Word). This finding is of particular clinical significance as elderly patients with executive dysfunction are less likely to remit using conventional antidepressants. In addition even if the depressive syndrome subsides, antidepressants are unlikely to improve executive deficits leaving them perpetually vulnerable to disability and relapse.

Further, our hypotheses regarding the cognitive benefits of nCCR-GD were confirmed. The nCCR-GD group exhibited improved cognitive performance on targeted executive functions. Near transfer of benefit was also observed in non-targeted but related executive functions. However, transfer to more distal cognitive functions (i.e. verbal memory; working memory) that rely on intact performance of executive functions did not improve post treatment. If these cognitive benefits are replicated, improved executive functioning through nCCR-GD may increase both the number of patients who are able to reach remission, as well as the number who are able to sustain prolonged remission.

Last, both affective and cognitive benefits observed from participation in nCCR-GD were sustained at least three months post completion. The sustainability of neurocognitive gains in our population are equivalent to those seen in other nCCR trials in normal aging^[@R45]^.

There are several important limitations that have variable impacts on the results of this preliminary study. We, therefore, encourage an appropriately tempered interpretation of these findings. The first is the study\'s small sample size. Given the small number of participants in this pilot trial, we can only speculate as to the generalizability of this finding. Second and perhaps most significant is the lack of an active, concurrently studied control group. The historical comparator group may not be an adequate comparison group due to multiple factors including the difference in duration, modality, and trial type. In addition to these effects, a control treatment provided in the same modality (computer) will be necessary to decipher whether targeted nCCR-GD is necessary to induce change in mood and cognitive symptoms of geriatric depression, or whether similar results could be achieved by non-specific stimulation. This last point is essential to the investigation of our hypothesis that targeting specific, and clinically relevant circuitry related to the pathophysiology of the illness is key to inducing both cognitive and affective change. Third, is the lack of prospective random assignment of subjects to the active and control groups. Though the groups were matched on clinically relevant variables, there are significant differences between the two groups for example: They were not similarly selected for prior treatment failure. Last, assessing neuropsychological performance before and after treatment required that some measures be repeated. Given that the treatments (escitalopram vs nCCR-GD) differed in length, it is possible that the difference in scores may be partially explained by a practice effect. However, 7 of the 10 nCCR-GD participants had already undergone the escitalopram trial and experienced the tests before entry to nCCR-GD.

Future Directions {#S9}
-----------------

This is a preliminary study conducted to test the feasibility of a nCCR in an elderly depressed population. Future iterations of this investigation will include larger samples randomized either to nCCR-GD or a concurrently studied, computer presented control condition. There are several control treatment options worth considering. For example, the use of a pre-packaged, non-targeted CCR intervention, a nCCR intervention targeted to a different neural circuit or an equally stimulating computer activity. A larger sample will allow for further investigation of the targeted neural circuits in the pathogenesis of geriatric depression as well as their relationship to treatment response by answering (for example): If changes in executive function induced by nCCR-GD are related to changes in depressive symptoms?; If executive dysfunction at baseline is a moderator of treatment response?; If targeting other circuitry achieves similar results or if this result is only achieved with specificity in target selection? nCCR-GD was designed to be mutable as well as to give incremental feedback to investigators about if the programs are performing as designed. As cognitive and affective neuroscience progresses, nCCR designs can progress in parallel, with new discoveries serving as targets for newly developed nCCR protocols.

In conclusion though the data are preliminary, nCCR-GD appears improve affective symptoms more quickly than escitalopram in patients who have previously failed to respond to pharmacotherapy. In addition, nCCR-GD may improve both targeted and non-targeted executive functions while escitalopram does not.

Methods {#S10}
=======

Participants {#S11}
------------

nCCR-GD participants were older adults (60-89) with major depression (by SCID-R/DSM-IV), who failed to achieve remission (Montgomery-Asberg Depression Rating Scale, MADRS\>15) after treatment with therapeutic dosages of an SSRI or SNRI antidepressant for at least 8 weeks ([Figure 5](#F5){ref-type="fig"}). In addition, we asked that they and their physicians had no plan to change medication or dosages for the duration of the study (4 weeks) unless required by significant worsening of clinical symptoms.

Weill Cornell Medical College Institutional Review Board reviewed and approved all procedures. 11 of 12 patients who met criteria and were approached signed informed consent and entered the study (mean age=73.5 years; sd=7.8). The sample was 63.6% female, 36.4% male. 8 of 11 Participants were recruited after failing to remit during a controlled 12-week escitalopram trial (target dose 20 mg). The other 3 participants were referred to the study by their psychiatrists after failing multiple trials of antidepressants. Of the 11 patients, 10 completed the four-week trial. One patient dropped at week 2 due to an inability to maintain the required frequency of clinic visits. All participants were questioned weekly about any changes to their medications; all maintained the same medication and dosage throughout the treatment period. Participants underwent a neuropsychological battery at baseline, after 4 weeks of treatment, and12-weeks post completion of nCCR-GD (week 16).

All participants met DSM-IV-TR criteria and Research Diagnostic Criteria for unipolar major depression and had a MADRAS score \> 15. Exclusion criteria were 1) major depression with psychotic features (according to DSM-IV-TR); 2) history of other psychiatric disorders (except personality disorders) before the onset of depression; 3) severe medical illness (i.e., metastatic cancer, brain tumors, unstable cardiac, hepatic, or renal disease, myocardial infarction, or stroke) within the 3 months preceding the study; 4) neurological disorders (i.e., dementia or delirium according to DSM-IV criteria, history of head trauma, Parkinson\'s disease, and multiple sclerosis); 5) conditions often associated with depression (i.e., endocrinopathies other than diabetes, lymphoma, and pancreatic cancer); 6) drugs causing depression (i.e., steroids, α-methyl-dopa, clonidine, reserpine, tamoxifen, and cimetidine); and 7) Mini-Mental State Examination ^[@R46]^ score \< 25 or Mattis Dementia Rating Scale scores below 130; 8) Amnestic or Multiple-Domain MCI; 9) Current psychotherapy; 10) Inability to speak English (nCCR-GD games are in English only); corrected visual acuity \<20/70 or color blindness. These criteria resulted in a group of elderly patients with non-psychotic unipolar major depression without a diagnosable dementing disorder.

### Comparison escitalopram participants {#S12}

Escitalopram participants included 30 matched (three escitalopram participants to each nCCR-GD participant) depressed, elderly (\> 60 years) patients from a university-based geriatric psychiatry clinic who were recruited for a 12-week escitalopram treatment trial. Each historical control was matched on three criteria: Age, depression severity, and executive dysfunction (Stroop CW performance). We chose these criteria due to their demonstrable effect on clinical outcomes in geriatric depression. Neuropsychological tests were performed during a 2-week single blind psychotropic drug wash out/placebo lead-in phase, and after 12-weeks of treatment. Escitalopram participants met DSM-IV-TR criteria and Research Diagnostic Criteria for unipolar major depression and had a score \> 19 on the 24-item Hamilton Depression Rating Scale (HDRS)^[@R47]^. Exclusion criteria were 1) major depression with psychotic features (according to DSM-IV-TR); 2) history of other psychiatric disorders (except personality disorders) before the onset of depression; 3) severe medical illness (i.e., metastatic cancer, brain tumors, unstable cardiac, hepatic, or renal disease, myocardial infarction, or stroke) within the 3 months preceding the study; 4) neurological disorders (i.e., dementia or delirium according to DSM-IV criteria, history of head trauma, Parkinson\'s disease, and multiple sclerosis); 5) conditions often associated with depression (i.e., endocrinopathies other than diabetes, lymphoma, and pancreatic cancer); 6) drugs causing depression (i.e., steroids, α-methyl-dopa, clonidine, reserpine, tamoxifen, and cimetidine); and 7) Mini-Mental State Examination^[@R46]^ score \< 25; 8) Current psychotherapy. These criteria resulted in a group of elderly patients with non-psychotic unipolar major depression without a diagnosable dementing disorder. Side effects of escitalopram were monitored with the Udvalg for Kliniske Undersøgelser (UKU) side effect scale^[@R48]^.

### Control escitalopram treatment {#S13}

Patients were informed that they would receive placebo at some point during their 14-week trial. After a 2-week psychotropic drug wash-out and single blind placebo lead-in, subjects who still met DSM-IV-TR criteria for major depression and had a 24-item HDRS score of 19 or greater received controlled treatment with escitalopram (target dose 20 mg) daily for 12 weeks. Patients were instructed to take a single dose of escitalopram in the morning, and were administered medication in one-week supply blisters that permitted dispensation of their daily dosage separately.

The treatment phase consisted of weekly follow up sessions beginning with the placebo lead-in, continuing until the 12th week of treatment with escitalopram. During each follow-up meeting, a research assistant administered the HDRS, MADRS the UKU, obtained vital signs, questioned the subjects about medication adherence, and counted the remaining tablets. This meeting was followed by a brief session with a research psychiatrist to assess the risk of continuing the treatment trial and to clinically confirm any remission. The session followed a medication clinic model consisting of a review of symptoms, explanations related to the need for treatment, and encouragement of treatment adherence. No subject received psychotherapy during the study.

### nCCR-GD {#S14}

Participants completed 30 hours of cognitive remediation over 4 weeks on computer stations in private treatment rooms at the Advanced Center for Interventions and Services Research (ACISR). The brief 4 week time period was chosen to mitigate several factors: The selected participants were treatment resistant and quite symptomatic; CCR-GD was an as-yet-untested treatment, and participants were continuing to take a dose of medication that was ineffective. Participants had access to the supervising psychologist and research assistants for questions at any time, but after the initial program set up, participants worked on their own without intervention.

Three "Bottom Up" training exercises were used: one low level auditory tone sweep and one phonemic discrimination task from "Brain Fitness" and one low level visual discrimination training exercise from "Insight"^[@R45],[@R49]^. These programs were designed for older adults to enhance basic processing of sensory stimuli with the goal to improve fidelity of initial auditory and visual encoding^[@R31],[@R45],[@R49]^.

"Top Down" training exercises were newly developed by our group and incorporated into two user interfaces. The first is "Catch the Ball": (Individually titrated training in visual attention, inhibition of prepotent responses, working memory, cognitive flexibility and dual task performance.): Participants view moving balls on a blue screen and are instructed to press the button when the ball turns to a target color. Balls change from yellow to the target or foil color (blue, red, green) at random intervals (1.5-3.5 sec). Initial difficulty levels focus on sustained attention, balls simply turn to the target color of red, with the duration of the target color progressively decreased to increase difficulty. Next levels introduce blue foils to require discriminatory attention and response inhibition. Next, response inhibition demands are increased and cognitive flexibility introduced by having the target switch back and forth between red and blue at random intervals. All variations are then repeated first with two balls on the screen and then with three to increase overall demand, and add divided attention demands. Speed at which the balls move is adaptively tracked. Subjects are moved from one difficulty level to the next when they demonstrate sustained accuracy at the fastest ball speed or when they fail to show continued performance at a slower speed. "Semantic Strategy": Training in recognition and initiation of semantic strategy. Participants are asked to rearrange multiple, increasingly complex word lists into categories with individually titrated decreases in allotted processing time. Task demands increase further by including components of "cognitive control"; using previous sort stimuli as proactive interference. Both speed and accuracy are adaptively tracked.

Training task parameters were set to keep performance between 75% and 85% correct; a balance between challenge and reward that in animal studies seems optimal for producing neuroplastic change. Participants selected the duration of sessions and a weekly schedule most desirable to them^[@R50]^. nCCR-GD programs give immediate auditory/visual rewards for correct responses^[@R51]^, and employ adaptive tracking of task difficulty in order to minimize frustration due to incorrect responses ^[@R45]^ as well as keeping performance levels in the desired range.

The Weill Cornell Medical College Institutional Review Board approved all procedures. After a complete description of the study to subjects, written informed consent was obtained.

### Outcome Measures {#S15}

Advanced Center for Interventions and Services Research (ACISR)-trained research assistants unaware of the study\'s hypotheses collected clinical ratings, neuropsychological tests and self-report measures under the supervision of a neuropsychologist (SSM).

Depressive symptoms were assessed using the 10-item MDRS. Disability was measured with the World Health Organization Disability Assessment Schedule-II (WHODAS-II). Baseline gross cognitive status was rated with the Mini-Mental State Examination^[@R46]^.

"Response" was defined as a 50% reduction in overall MADRS from baseline to end of treatment. "Remission" was defined as a MADRS score of 10 or less^[@R44]^.

Neuropsychological measures: Overall cognitive dysfunction was assessed with the Mattis Dementia Rating Scale (DRS). Executive functioning was assessed in both groups with two measures: Inhibiting prepotent responses with the Stroop Color-Word Test ^[@R52]^, and cognitive flexibility with Trail Making Test B^[@R53]^. In the nCCR-GD group we also assessed semantic clustering with semantic clusters on the Mattis Dementia Rating Scale Complex Verbal Test, verbal memory with the CVLT-ii long delay recall; non-verbal cognitive flexibility with design fluency-switching from the Delis Kaplan Executive Functioning System (DKEF-S); and working memory with digits backwards from the WAIS-IV. Alternate forms, where available, were used during the second administration. These tests were not administered to the escitalopram group and, therefore, scores could not be compared.

Statistical Analysis {#S16}
====================

Baseline demographic and clinical characteristics of the two treatment groups were compared using Mann-Whitney U statistics. Efficacy (MADRS score over time) of treatment groups was compared with longitudinal mixed models analysis with a random intercept and time (weeks from baseline), treatment group, and a time by treatment group interaction as fixed effects. As nCCR-GD was designed to improve executive functions, we compared the change in executive test scores (Trails B, Stroop CW) over time (baseline, end of study) between the two treatment groups with repeated measures ANOVAs. We performed paired t-tests to compare scores on tests of executive function from baseline, to the end of nCCR-GD treatment (4 weeks), and 4-weeks to 12 weeks (or week 16 of the study) post treatment. The relationship between change in depressive symptoms and change in executive function was evaluated with Spearman\'s Rho.

[Author Contributions:]{.ul} S.S.M., G.S.A, and B.W. conceived the research and designed the study. S.S.M., B.W., J.L., and W.H., designed the computer programs. S.S.M, W.H., and J.S. collected the data and administered the intervention, while S.S.M and G.S.A were clinical consultants to participants. J.L. and W.H. assisted by S.S.M analyzed the computer-generated participant data. S.S.M. performed the statistical analysis assisted by J.S. Interpretation of results was performed by S.S.M, B.W., and G.S.A. The manuscript was written and revised by S.S.M. with assistance from B.W. and G.S.A. All authors critically reviewed the manuscript for important intellectual content and approved the final submitted manuscript.

[Competing financial interests:]{.ul} B.W.is Founder and Chief Scientist of C8 Sciences which sells brain training programs to improve executive function in young children. B.W. played no role in the selection of patients or assessment of outcomes in this research.J; G.S.is on the Speaker\'s Bureau for: Astra Zeneca, Novartis, Sunovion, Takeda-Lundbeck. All other authors declare no competing financial interests.

![Participant data. Depiction of participants\' depression scores on the Montgomery-Asberg Depression Rating Scale (MADRS) by each week of treatment. Twelve weeks for the escitalopram group and 4 weeks for the nCCR-GD group.](nihms610895f1){#F1}

![Mixed Models Predicted Values. Efficacy (MADRS score over time) of treatment groups was compared with longitudinal mixed models analysis with a random intercept and time (weeks from baseline), treatment group, and a time by treatment group interaction as fixed effects.](nihms610895f2){#F2}

![Changes in time to complete trails. Depiction of the change from baseline to post treatment in participants treated with escitalopram and participants treated with nCCR-GD on the Trail Making Test part B, a test of executive function measuring cognitive flexibility.](nihms610895f3){#F3}

![Changes in Stroop Color-Word. Figure 4 depicts the change from baseline to post treatment in participants treated with escitalopram and participants treated with nCCR-GD on the Stroop Color-Word, a test of executive function measuring inhibition of prepotent responses.](nihms610895f4){#F4}

![CCR-GD Participant Antidepressant Medications. Figure 5 depicts the antidepressant medications taken for at least 8 weeks by nCCR-GD participants throughout the 4 weeks of treatment. No participant changed their medications or dosages throughout the study.](nihms610895f5){#F5}

###### 

Baseline participant characteristics.

                           CCR-GD         escitalopram   Mann-Whitney U   Significance
  ------------------------ -------------- -------------- ---------------- --------------
  **Baseline MADRS**       25.7 (7.3)     25.3 (5.9)     180.0            0.967
  **Executive Function**   157.4 (65.1)   145.3 (68.5)   152.0            0.424
  **Age**                  74.1 (7.81)    73.1 (6.95)    173.0            0.818
  **Education**            15.7 (2.7)     14.5 (4.1)     141.5            0.273
  **Age of Onset**         45.9 (24.6)    52.6 (23.2)    153.0            0.440

Baseline characteristics for 11 CCR-GD patients and 33 age, depression severity, and executive function-matched historical controls.
